/
ACON
$2.89+$0.04 (+1.40%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.0M
2M shares
52-week range
$2.34 – $12.03
6% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-393635.51
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $26.9K | $48.7K | $60.3K | $60.4K | $75.4K | $45.7K | $75.7K |
| Cost of revenue | $63.2K | $66.2K | $69.2K | $65.3K | $75.7K | $129.8K | $296.3K |
| Gross profit | −$36.3K | −$17.6K | −$8.9K | −$4.9K | −$324 | −$84.0K | −$220.6K |
| Gross margin | -134.9% | -36.2% | -14.7% | -8.0% | -0.4% | -183.8% | -291.3% |
| R&D | $1.7M | $1.1M | $787.9K | $1.1M | $873.3K | $888.8K | $1.03T |
| Operating income | −$4.0M | −$4.5M | −$3.0M | −$5.6M | −$4.9M | −$5.5M | −$7.1M |
| EBITDA | −$3.8M | −$4.3M | −$4.3M | −$5.4M | −$4.1M | −$6.3M | −$7.0M |
| Net income | −$4.0M | −$4.6M | −$5.0M | −$7.1M | −$4.9M | −$7.0M | −$7.2M |
| Net margin | -14943.1% | -9527.3% | -8210.5% | -11694.4% | -6513.4% | -15293.8% | -9551.9% |
| EPS (diluted) | -97680.00 | -110583.00 | -120035.00 | -177396.00 | -79782.00 | -7480.22 | -13.61 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $140000 | $-4.51 | $-4.51–$-4.51 | 1 |
| 2027 | $260000 | $-5.37 | $-5.37–$-5.37 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$20.52
Price
$2.89
Implied upside
+610%
Peer comparison
Aclarion, Inc. Common Stock
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
www.aclarion.com- Employees
- 11
- IPO / List date
- Apr 22, 2022
- HQ
- BROOMFIELD, CO
Held by traders on TradeandTell
No one on the platform currently holds ACON.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ACON as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-03-28 | 1-for-27reverse |
| 2025-01-30 | 1-for-335reverse |
| 2024-01-04 | 1-for-16reverse |
Recent trades on TradeandTell
No one on the platform has traded ACON yet.
